Stock Notes

Mankind Pharma

Every Finvezto stock note on Mankind Pharma, dated and newest first. Coverage spans pharma.

2 notes and counting
20 Aug 2026
Mankind Pharma took exclusive India rights to insulin degludec and the degludec plus aspart combination from China's Chongqing Chenan Biopharmaceutical.
The two products are versions of Novo Nordisk's Tresiba and Ryzodeg. Mankind's diabetes portfolio runs at Rs 1,073 crore on a moving annual basis with a 4.4 percent share, so it is buying an ultra-long-acting insulin line rather than spending years developing one.
21 May 2026
Mankind Pharma guides for double-digit top-line growth and EBITDA margins of 25.5% to 26.5% in FY27.
The margin band is among the strongest in mid-cap pharma, reflecting Mankind's acute therapy dominance and low-cost domestic manufacturing base.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.